Matches in Wikidata for { <http://www.wikidata.org/entity/Q64217457> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q64217457 description "assaig clínic" @default.
- Q64217457 description "clinical trial" @default.
- Q64217457 description "clinical trial" @default.
- Q64217457 description "clinical trial" @default.
- Q64217457 description "clinical trial" @default.
- Q64217457 description "ensaio clínico" @default.
- Q64217457 description "ensayo clínico" @default.
- Q64217457 description "ensayu clínicu" @default.
- Q64217457 description "essai clinique" @default.
- Q64217457 description "klinisch onderzoek" @default.
- Q64217457 description "клінічне випробування" @default.
- Q64217457 name "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetax" @default.
- Q64217457 type Item @default.
- Q64217457 label "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetax" @default.
- Q64217457 prefLabel "Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetax" @default.
- Q64217457 P1132 Q64217457-F069016B-F006-4A0C-866C-BAE52A247525 @default.
- Q64217457 P1476 Q64217457-C6BD443A-1B57-4BB6-B2D9-7BD32386BBFB @default.
- Q64217457 P17 Q64217457-499C50E6-302A-4F01-9820-C8DD955F0C62 @default.
- Q64217457 P17 Q64217457-87114621-AABD-42DE-AF70-10A2CE11C254 @default.
- Q64217457 P2899 Q64217457-4490C3DE-FE4C-45A1-B4D1-A0DE9B1E42BA @default.
- Q64217457 P3098 Q64217457-A34C41B0-1B15-464E-AE5B-95361A8B8E2E @default.
- Q64217457 P31 Q64217457-9E087489-754F-4965-9789-4CEC5E0E954B @default.
- Q64217457 P4844 Q64217457-809A56B4-66A1-4693-9CAB-70DFB867944C @default.
- Q64217457 P580 Q64217457-F160E2D7-0521-4F4D-B3F5-F7B3227BD1AE @default.
- Q64217457 P582 Q64217457-30261CCB-3928-4ED5-A451-C0287493B920 @default.
- Q64217457 P6099 Q64217457-523905FC-858E-4B58-9A38-FD175EF8DDBD @default.
- Q64217457 P6153 Q64217457-3A6D903A-45F2-4434-895C-7C55960F02B7 @default.
- Q64217457 P6153 Q64217457-47775137-BD92-4F26-A5C4-1312F4451556 @default.
- Q64217457 P6153 Q64217457-93B90A0C-97E9-4583-806E-4B2631F55FC2 @default.
- Q64217457 P6153 Q64217457-C2D5E8C8-DCC1-45B4-83A3-B5974830011F @default.
- Q64217457 P6153 Q64217457-C464F1DB-1889-4E75-99C2-05FB5DB4013A @default.
- Q64217457 P6153 Q64217457-E5343E61-EA01-43CF-AA43-CFF0288AEF82 @default.
- Q64217457 P8363 Q64217457-EEAD5DC2-76B1-49AA-AEB9-85E934DF4F86 @default.
- Q64217457 P859 Q64217457-B03878A9-7B67-4104-97B9-100DDAEE0E9B @default.
- Q64217457 P1132 "+329" @default.
- Q64217457 P1476 "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer" @default.
- Q64217457 P17 Q865 @default.
- Q64217457 P17 Q869 @default.
- Q64217457 P2899 "+18" @default.
- Q64217457 P3098 "NCT02586025" @default.
- Q64217457 P31 Q30612 @default.
- Q64217457 P4844 Q1998021 @default.
- Q64217457 P580 "2016-03-14T00:00:00Z" @default.
- Q64217457 P582 "2017-10-23T00:00:00Z" @default.
- Q64217457 P6099 Q42824827 @default.
- Q64217457 P6153 Q11141679 @default.
- Q64217457 P6153 Q30253907 @default.
- Q64217457 P6153 Q30260510 @default.
- Q64217457 P6153 Q39997 @default.
- Q64217457 P6153 Q495015 @default.
- Q64217457 P6153 Q701818 @default.
- Q64217457 P8363 Q78089383 @default.
- Q64217457 P859 Q212646 @default.